Table 3.
Open in new tab

Antimicrobial susceptibility at our institution

Antimicrobial agentMinocycline (n = 23)Trimethoprim/sulfamethoxazole (n = 22)
Cefepime4 (17%)5 (23%)
Ceftazidime8 (35%)13 (59%)
Moxifloxacin17 (74%)17 (77%)
Ticarcillin/clavulanate13 (57%)15 (68%)
Trimethoprim/sulfamethoxazole20 (87%)22 (100%)
Minocycline23 (100%)22 (100%)
Antimicrobial agentMinocycline (n = 23)Trimethoprim/sulfamethoxazole (n = 22)
Cefepime4 (17%)5 (23%)
Ceftazidime8 (35%)13 (59%)
Moxifloxacin17 (74%)17 (77%)
Ticarcillin/clavulanate13 (57%)15 (68%)
Trimethoprim/sulfamethoxazole20 (87%)22 (100%)
Minocycline23 (100%)22 (100%)
Table 3.
Open in new tab

Antimicrobial susceptibility at our institution

Antimicrobial agentMinocycline (n = 23)Trimethoprim/sulfamethoxazole (n = 22)
Cefepime4 (17%)5 (23%)
Ceftazidime8 (35%)13 (59%)
Moxifloxacin17 (74%)17 (77%)
Ticarcillin/clavulanate13 (57%)15 (68%)
Trimethoprim/sulfamethoxazole20 (87%)22 (100%)
Minocycline23 (100%)22 (100%)
Antimicrobial agentMinocycline (n = 23)Trimethoprim/sulfamethoxazole (n = 22)
Cefepime4 (17%)5 (23%)
Ceftazidime8 (35%)13 (59%)
Moxifloxacin17 (74%)17 (77%)
Ticarcillin/clavulanate13 (57%)15 (68%)
Trimethoprim/sulfamethoxazole20 (87%)22 (100%)
Minocycline23 (100%)22 (100%)
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close